A phase 1 study of prasugrel in patients with sickle cell disease: Effects on biomarkers of platelet activation and coagulation

Thrombosis Research

Volumn 133, Issue 2, 2014, Pages 190-195

  Jakubowski, Joseph A ^a   Zhou, Chunmei ^a   Jurcevic, Stipo ^b   Winters, Kenneth J ^a   Lachno, D Richard ^a   Frelinger III, Andrew L ^c   Gupta, Neehar ^a   Howard, Jo ^d   Payne, Christopher D ^a   Mant, Timothy G ^e  

^a ELI LILLY AND COMPANY   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e GUY S HOSPITAL   (United Kingdom)

Author keywords

ADP; Biomarkers; P2Y12 receptor antagonist; Platelets; Prasugrel; Sickle cell disease

Indexed keywords

BIOLOGICAL MARKER; CD40 LIGAND; FIBRINOGEN RECEPTOR; PADGEM PROTEIN; PRASUGREL; THROMBOPLASTIN;

ADULT; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ERYTHROCYTE AGGREGATION; FEMALE; HUMAN; LEUKOCYTE AGGREGATION; MALE; MONOCYTE; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SICKLE CELL ANEMIA; SINGLE DRUG DOSE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ADENOSINE DIPHOSPHATE; ADP; BIOMARKERS; CD40 LIGAND; CD40L; EDTA; ETHYLENEDIAMINETETRAACETIC ACID; GLYCOPROTEIN IIB-IIIA; GPIIBIIIA; P2Y(12) RECEPTOR ANTAGONIST; PD; PHARMACODYNAMICS; PHARMACOKINETICS; PK; PLATELETS; PRASUGREL; RBCS; RED BLOOD CELLS; SCD; SD; SICKLE CELL DISEASE; STANDARD DEVIATION; TF; THROMBOXANE B(2); TISSUE FACTOR; TXB(2); VASO-OCCLUSIVE CRISIS; VOC;

ADENOSINE DIPHOSPHATE; ADULT; ANEMIA, SICKLE CELL; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD PLATELETS; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLATELET ACTIVATION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES; YOUNG ADULT;

EID: 84892365065     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2013.12.008     Document Type: Article

References (30)

1. World Health Organization Genes and Human Disease: Sickle Cell Anemia c2012 [cited 2013 Apr 24]. Available from: http://www.who.int/genomics/public/ geneticdiseases/en/index2.html#SCA
2. L. Charneski, and H.B. Congdon Effects of antiplatelet and anticoagulant medications on the vasoocclusive and thrombotic complications of sickle cell disease: A review of the literature Am J Health Syst Pharm 67 2010 895 900
3. G.R. Serjeant Sickle-cell disease Lancet 350 1997 725 730
4. M.H. Steinberg Management of sickle cell disease N Engl J Med 340 1999 1021 1030
5. S.P. Lee, K.I. Ataga, E.P. Orringer, D.R. Phillips, and L.V. Parise Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation Arterioscler Thromb Vasc Biol 26 2006 1626 1631
6. K.I. Ataga, M.D. Cappellini, and E.A. Rachmilewitz Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability Br J Haematol 139 2007 3 13
7. R.B. Francis Jr. Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion Blood Coagul Fibrinolysis 2 1991 341 353
8. K.I. Ataga, and E.P. Orringer Hypercoagulability in sickle cell disease: a curious paradox Am J Med 115 2003 721 728
9. T. Wun, T. Paglieroni, F. Tablin, J. Welborn, K. Nelson, and A. Cheung Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia J Lab Clin Med 129 1997 507 516
10. J.A. Jakubowski, K.J. Winters, H. Naganuma, and L. Wallentin Prasugrel: A novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile Cardiovasc Drug Rev 25 2007 358 374
11. D.P. Inwald, F.J. Kirkham, M.J. Peters, R. Lane, A. Wade, J.P. Evans, and N.J. Klein Platelet and leucocyte activation in childhood sickle cell disease: association with nocturneal hypoxaemia Br J Haematol 111 2000 474 481
12. A. Tomer, L.A. Harker, S. Kasey, and J.R. Eckman Thrombogenesis in sickle cell disease J Lab Clin Med 137 2001 398 407
13. C. Beurling-Harbury, and S.G. Schade Platelet activation during pain crisis in sickle cell anemia patients Am J Hematol 31 1989 237 241
14. M.J. Semple, S.F. Al-Hasani, and G.F. Savidge A double-blind trial of ticlopidine in sickle cell disease Thromb Haemost 51 1984 303 306
15. R. Cabannes, J. Lonsdorfer, J.P. Castaigne, A. Ondo, A. Plassard, and I. Zohoun Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises Agents Actions Suppl 15 1984 199 212
16. D.S. Small, Y.G. Li, C.S. Ernest, J.H. April, N.A. Farid, C.D. Payne, K.J. Winters, S. Rohatagi, and L. Ni Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent J Clin Pharmacol 51 2011 321 332
17. J.A. Jakubowski, C.D. Payne, Y.G. Li, J.T. Brandt, D.S. Small, N.A. Farid, D.E. Salazar, and K.J. Winters The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration Thromb Haemost 99 2008 409 415
18. J.A. Jakubowski, C. Zhou, D.S. Small, K.J. Winters, D.R. Lachno, A.L. Frelinger III, J. Howard, T.G. Mant, S. Jurcevic, and C.D. Payne A Phase 1 Study of Prasugrel in Patients with Sickle Cell Disease: Pharmacokinetics and Effects on ex Vivo Platelet Reactivity Br J Clin Pharmacol 75 2013 1433 1444
19. M.R. Barnard, M.D. Linden, A.L. Frelinger III, Y. Li, M.L. Fox, M.I. Furman, and A.D. Michelson Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity J Thromb Haemost 3 2005 2563 2570
20. A.L. Frelinger III, J.A. Jakubowski, Y. Li, M.R. Barnard, M.D. Linden, I. Tarnow, M.L. Fox, A. Sugidachi, K.J. Winters, M.I. Furman, and A.D. Michelson The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin Thromb Haemost 98 2007 192 200
21. M.I. Furman, D.J. Kereiakes, L.A. Krueger, M.N. Mueller, K. Pieper, T.M. Broderick, J.F. Schneider, W.L. Howard, M.L. Fox, M.R. Barnard, A.L. Frelinger, and A.D. Michelson et al. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab Am Heart J 142 2001 790 798
22. M. Berny-Lang, A.L.I. Frelinger, M.R. Barnard, and A.D. Michelson Flow Cytometry A.D. Michelson, Platelets 3rd ed. 2012 Academic Press San Diego 581 602
23. M.R. Panara, G. Renda, M.G. Sciulli, G. Santini, M. Di Giamberardino, M.T. Rotondo, S. Tacconelli, F. Seta, C. Patrono, and P. Patrignani Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects J Pharmacol Exp Ther 290 1999 276 280
24. M.E. Nesheim, J.B. Taswell, and K.G. Mann The contribution of bovine Factor V and Factor Va to the activity of prothrombinase J Biol Chem 254 1979 10952 10962
25. L. Ziegler-Heitbrock The CD14 + CD16 + blood monocytes: their role in infection and inflammation J Leukoc Biol 81 2007 584 592
26. A.L. Frelinger III, J.A. Jakubowski, Y. Li, M.R. Barnard, M.D. Linden, I. Tarnow, M.L. Fox, A. Sugidachi, K.J. Winters, M.I. Furman, and A.D. Michelson The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities J Thromb Haemost 6 2008 359 365
27. T. Wun, D. Soulieres, A.L. Frelinger, L. Krishnamurti, E.M. Novelli, A. Kutlar, K.I. Ataga, C.L. Knupp, L. McMahon, J.J. Strouse, C. Zhou, L.E. Heath, C.E. Nwachuku, J.A. Jakubowski, J.S. Riesmeyer, and K.J. Winters A Double-Blind, Randomized, Multicenter Phase 2 Study of Prasugrel versus Placebo in Adult Patients with Sickle Cell Disease J Hematol Oncol 6 2013 17
28. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, S. Gottlieb, F.J. Neumann, D. Ardissino, S. De Servi, S.A. Murphy, J. Riesmeyer, G. Weerakkody, and C.M. Gibson Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
29. J.B. Schnog, A.P. Kater, M.R. Mac Gillavry, A.J. Duits, L.R. Lard, F.P. van Der Dijs, D.P. Brandjes, H. ten Cate, L.W. van Eps, and R.A. Rojer Low adjusted-dose acenocoumarol therapy in sickle cell disease: a pilot study Am J Hematol 68 2001 179 183
30. H.J. Wolters, H. ten Cate, L.L. Thomas, D.P. Brandjes, A. van der Ende, and Y. van der Heiden Statius van Eps LW. Low-intensity oral anticoagulation in sickle-cell disease reverses the prethrombotic state: promises for treatment? Br J Haematol 90 1995 715 717